After a historic sell-off with stocks plummeting by more than 50 percent, can biotech bounce back? What might be driving this disinvestment despite increased new drug approvals by the FDA and generally higher interest in the sector? Is the disinvestment a result of the increased focus on platform technologies and trends such as artificial intelligence? These may be short-term setbacks, so what does the near future look like for this critical sector? Will innovation continue to drive growth? Where are the areas of greatest opportunity and unmet need?  

Moderator

Lisa Suennen

CEO, Venture Valkyrie Consulting

Speakers

Christopher Austin

CEO-Partner, Vesalius Therapeutics, Flagship Pioneering

Luciana Borio

Venture Partner, ARCH Venture Partners

Wei Fu

CEO, CBC Group

Pablo Legorreta

Founder and CEO, Royalty Pharma

Jim Tananbaum

Founder and CEO, Foresite Capital Management, LLC